Study details
Enrolling now
iExosomes for Pancreatic Cancer
M.D. Anderson Cancer Center
NCT IDNCT03608631ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
28
Study length
about 6.3 years
Ages
18+
Locations
1 site in TX
About this study
This trial is testing a new treatment, iExosomes, in people with metastatic pancreas cancer that has a KrasG12D mutation. The goal is to find the best dose and see if iExosomes can help treat this type of pancreatic cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
PhasePhase 1/Phase 2
Primary goalMaximum Tolerated Dose Determined by Dose Limiting Toxicity
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Maximum Tolerated Dose Determined by Dose Limiting Toxicity, Overall survival (OS), Progression-free survival (PFS)
Body systems
Oncology